Welcome to our dedicated page for Veeva Systems news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Systems stock.
Veeva Systems Inc. (NYSE: VEEV) is a global leader in cloud-based software solutions specifically tailored for the life sciences industry. Headquartered in the San Francisco Bay Area, Veeva Systems provides innovative technology that helps pharmaceutical and biotech companies streamline their operations, ensure compliance, and bring products to market faster. Veeva's product offerings address key operational and regulatory needs, ranging from customer relationship management (CRM) to content management and data analytics.
Two of the company's flagship products include Veeva CRM and Veeva Vault. Veeva CRM is designed for companies with a salesforce, providing tools to manage customer interactions more efficiently. Meanwhile, Veeva Vault is a versatile content management platform that supports various functions such as clinical trials, regulatory submissions, and quality management within life sciences companies.
Veeva serves a diverse customer base, ranging from emerging biotechs to some of the world's largest pharmaceutical companies. Its commitment to product excellence, customer success, and continuous innovation is evident as Veeva frequently updates its offerings to meet the evolving needs of the industry. Recently, Veeva announced that Boehringer Ingelheim has selected Veeva Vault Clinical and Veeva Vault RIM applications to streamline clinical execution and improve regulatory management in its animal health business unit.
Another notable achievement for Veeva was the launch of the Veeva AI Partner Program, designed to help partners integrate Generative AI solutions seamlessly with Veeva Vault applications. This initiative highlights Veeva's ongoing efforts to leverage advanced technologies to enhance its product ecosystem. Furthermore, the introduction of Veeva Vault CRM Campaign Manager aims to simplify and speed up non-personal promotion to healthcare professionals, ensuring consistent and compliant marketing efforts.
Financially, Veeva Systems has shown strong performance with its fiscal year 2024 results reflecting robust growth. The company continues to invest in its innovation engine and strategic partnerships, setting the stage for sustained, profitable growth. Veeva's recent financial outlook for fiscal year 2025 and first quarter results for 2024 further underline its market leadership and operational excellence.
For more information about Veeva Systems, its products, and latest updates, visit www.veeva.com.
Veeva Systems (NYSE: VEEV) has announced a major release of Veeva Site Connect, enhancing clinical trial execution for sites and sponsors. The update includes new capabilities and a streamlined site-centric experience to simplify sponsor-site collaboration. Key features include:
1. Expanded functionality beyond document exchange and safety distribution
2. Optimized site user interface standardized across all trials
3. Open accessibility for all sites globally
4. Fixed-price implementation with 2-4 month setup
Seven of the top 20 biopharmas have already adopted Veeva Site Connect, aiming to reduce time and effort in site start-up, study conduct, and closeout. The platform is part of Veeva Clinical Platform, supporting patients, sites, and sponsors in streamlining clinical trials.
Veeva Systems (NYSE: VEEV) has announced its participation in the upcoming Citi 2024 Global TMT Conference in New York. Paul Shawah, EVP Strategy at Veeva, is scheduled to present on Wednesday, September 4, 2024, at 3:00 p.m. Eastern Time.
The presentation will be webcast live and archived for later viewing. Interested parties can access the webcast through Veeva's investor relations website at https://ir.veeva.com. This event provides an opportunity for investors and analysts to gain insights into Veeva's strategies and market position in the technology, media, and telecommunications sectors.
Veeva Systems (NYSE: VEEV) reported strong fiscal 2025 Q2 results, with total revenues of $676.2M, up 15% year-over-year, and subscription services revenues of $561.3M, up 19% year-over-year. The company's operating income increased 60% to $166.5M, while non-GAAP operating income rose 32% to $279.8M. Net income grew 53% to $171.0M, with non-GAAP net income up 35% to $267.3M.
Veeva highlighted key product advances, including the release of Vault CRM Service Center and enhancements to Veeva Site Connect. The company also provided guidance for Q3 FY2025, projecting total revenues between $682M and $685M, and updated its full-year FY2025 guidance to total revenues between $2,704M and $2,710M.
Veeva Systems (NYSE: VEEV) has unveiled Veeva Vault CRM Service Center, a new addition to its Vault CRM Suite. This tool is designed for inside sales, contact center, and hybrid representatives in the life sciences industry. It offers case management, video calls, telephony integration, and industry-specific features like consent and sampling. The Service Center integrates with Microsoft 365, enhancing productivity through collaboration in Teams and OneNote.
The Vault CRM Suite aims to unify sales, marketing, medical, and service teams, eliminating silos and providing a customer-centric experience. It includes Vault CRM for sales and Campaign Manager for marketing, all built on the Vault Platform. The suite offers compliant omnichannel engagement, events management, and AI-powered insights. Over 15 companies are already using Vault CRM, with migrations for smaller customers starting in Q4 2024 and larger ones in early 2025.
Veeva Systems (NYSE: VEEV) announced increasing momentum for Veeva Vault LIMS, a cloud solution that simplifies quality control (QC) processes. Vault LIMS is unified with Veeva Vault Quality, enabling customers to share data across quality applications for more informed batch release decisions. The solution aims to bring together quality assurance (QA) and QC to improve efficiency, compliance, and right-first-time execution.
Forge Biologics' senior director of QC analytical testing, Andrew Laughhunn, highlighted the potential for streamlined method execution and minimized documentation errors. Vault LIMS offers a complete QC management and test execution solution that can be deployed quickly, reducing reliance on IT teams and lowering total cost of ownership. The solution is suitable for both established organizations and fast-growing biotechs.
Veeva Systems (NYSE: VEEV) has announced the upcoming 2024 Veeva R&D and Quality Summit in Boston on Sept. 9-10. This event, one of the largest in life sciences, will bring together over 2,000 industry professionals to discuss how connected systems across clinical, regulatory, safety, and quality can advance drug development.
Keynote speakers from leading companies like AbbVie, Astellas, Eikon Therapeutics, Merck & Co., Moderna, and Roche will share insights on various topics. These include pharmacovigilance transformation, clinical process optimization, scalable development foundations, quality control modernization, and AI-powered translation for faster submissions.
Veeva CEO Peter Gassner will headline the opening keynote, focusing on how connected data and systems can streamline drug development and accelerate product time to market. The summit will feature over 100 sessions, providing ample networking and learning opportunities for attendees.
Veeva Systems (NYSE: VEEV) has announced that it will release its fiscal 2025 second quarter financial results on August 28, 2024, after the market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted to Veeva's investor relations website approximately at 1:05 p.m. PT (4:05 p.m. ET). Investors and analysts can register for the conference call, and a webcast replay will be available on the company's website following the live event.
Veeva Systems' latest Pulse Field Trends Report reveals that targeted pre-launch scientific outreach significantly accelerates treatment adoption. Key findings include:
1. Biopharmas investing in pre-launch scientific activities and prioritizing congresses achieve 40% faster treatment adoption.
2. Early-career experts are four times more likely to start patients on new treatments and more open to digital engagement.
3. Congress activity has the strongest influence on clinical decisions post-approval.
4. Engaging early-career HCPs increases new treatment uptake, with these experts being five times more likely to speak at congresses and 11 times more likely to engage digitally.
The report emphasizes the importance of expanding engagement strategies beyond traditional experts and investing in different types of scientific outreach to drive greater impact and faster treatment adoption.
Veeva Systems (NYSE: VEEV) announced a partnership with Vita Global Sciences to enhance clinical data management through Veeva Vault EDC. This collaboration aims to streamline processes, improve patient and stakeholder experiences, and accelerate study builds. Kelly Forester, director of clinical data management at Vita Global Sciences, highlighted the goal of delivering impactful innovations. Future plans include integrating Veeva Clinical Database (CDB) and Veeva RTSM to further optimize trial data management and patient randomization. Jon Young from Veeva emphasized that these advancements will help Vita Global Sciences achieve faster, more accurate trials.
Veeva Systems (NYSE: VEEV) announced that Hangzhou Tigermed Consulting has chosen Veeva Vault EDC as its foundational technology for electronic data capture (EDC). This adoption is expected to streamline complex data management processes, enabling faster study builds and mid-study amendments without downtime. Tigermed aims to enhance clinical trial management and data quality, benefiting both their clients and the broader industry. The collaboration with Veeva aligns with Tigermed's ongoing investment in new technology to maintain a competitive edge in clinical research. Veeva Vault EDC is part of Veeva's Clinical Platform, widely used by top biopharmaceutical companies and contract research organizations (CROs).
FAQ
What is the current stock price of Veeva Systems (VEEV)?
What is the market cap of Veeva Systems (VEEV)?
What does Veeva Systems Inc. do?
Where is Veeva Systems Inc. headquartered?
What are Veeva's main products?
Who are Veeva Systems' customers?
What recent partnerships has Veeva announced?
What is the Veeva AI Partner Program?
How has Veeva performed financially recently?
What is Veeva Vault CRM Campaign Manager?
What industry does Veeva Systems primarily serve?
How does Veeva contribute to the life sciences industry?
